On Friday, Zevra Therapeutics Inc (NASDAQ: ZVRA) was 3.37% up from the session before settling in for the closing price of $7.13. A 52-week range for ZVRA has been $3.89 – $8.44.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 44.97%. When this article was written, the company’s average yearly earnings per share was at -22.00%. With a float of $52.20 million, this company’s outstanding shares have now reached $52.62 million.
Let’s determine the extent of company efficiency that accounts for 69 employees. In terms of profitability, gross margin is 46.32%, operating margin of -309.83%, and the pretax margin is -273.36%.
Zevra Therapeutics Inc (ZVRA) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Zevra Therapeutics Inc stocks. The insider ownership of Zevra Therapeutics Inc is 0.79%, while institutional ownership is 30.57%. The most recent insider transaction that took place on Jul 17 ’24, was worth 13,540. In this transaction CFO & Treasurer of this company bought 2,000 shares at a rate of $6.77, taking the stock ownership to the 18,469 shares. Before that another transaction happened on Jul 16 ’24, when Company’s Director bought 10,000 for $6.81, making the entire transaction worth $68,065. This insider now owns 20,000 shares in total.
Zevra Therapeutics Inc (ZVRA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -22.00% per share during the next fiscal year.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Trading Performance Indicators
You can see what Zevra Therapeutics Inc (ZVRA) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 2.00. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.68, a number that is poised to hit -0.42 in the next quarter and is forecasted to reach -0.41 in one year’s time.
Technical Analysis of Zevra Therapeutics Inc (ZVRA)
Looking closely at Zevra Therapeutics Inc (NASDAQ: ZVRA), its last 5-days average volume was 0.85 million, which is a jump from its year-to-date volume of 0.42 million. As of the previous 9 days, the stock’s Stochastic%D was 40.17%. Additionally, its Average True Range was 0.56.
During the past 100 days, Zevra Therapeutics Inc’s (ZVRA) raw stochastic average was set at 74.77%, which indicates a significant increase from 64.22% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 138.72% in the past 14 days, which was higher than the 76.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.67, while its 200-day Moving Average is $5.41. However, in the short run, Zevra Therapeutics Inc’s stock first resistance to watch stands at $7.54. Second resistance stands at $7.70. The third major resistance level sits at $7.92. If the price goes on to break the first support level at $7.15, it is likely to go to the next support level at $6.93. Now, if the price goes above the second support level, the third support stands at $6.77.
Zevra Therapeutics Inc (NASDAQ: ZVRA) Key Stats
There are 41,853K outstanding shares of the company, which has a market capitalization of 387.81 million. As of now, sales total 27,460 K while income totals -46,050 K. Its latest quarter income was 3,430 K while its last quarter net income were -16,620 K.
